Adeno-associated virus serotype 8 (AAV8) delivery of recombinant A20 to skeletal muscle reduces pathological Activation of Nuclear Factor (NF)-κB in muscle of mdx mice

Molecular Medicine

Volumn 18, Issue 12, 2012, Pages 1527-1535

  Charan, Rakshita A ^a,b   Niizawa, Gabriela ^a,b   Nakai, Hiroyuki ^c   Clemens, Paula R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; MYOGENIC FACTOR 5; MYOSIN HEAVY CHAIN; PARVOVIRUS VECTOR; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN A20; TRANSCRIPTION FACTOR RELB; TRUNCATED MUSCLE CREATINE KINASE; UNCLASSIFIED DRUG;

A20 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; GASTROCNEMIUS MUSCLE; GENE OVEREXPRESSION; GENE TRANSFER; INFLAMMATORY CELL; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MALE; MOUSE; MUSCLE NECROSIS; MUSCLE REGENERATION; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL NUCLEUS; DEPENDOVIRUS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED MDX; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MYOGENIC REGULATORY FACTOR 5; NECROSIS; NF-KAPPA B; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS; REGENERATION; SEROTYPING; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTION FACTOR RELB; UBIQUITIN-PROTEIN LIGASES;

EID: 84873497731     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00299     Document Type: Article

References (46)

1. Emery AE. (1991) Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscul. Disord. 1:19-29.
2. Hoffman E, Brown R, Kunkel L. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 51:919-28.
3. Matsumura K, Ervasti JM, Ohlendieck K, Kahl SD, Campbell KP. (1992) Association of dystrophin-related protein with dystrophinassociated proteins in mdx mouse muscle. Nature. 360:588-91.
4. Pierno S, et al. (2007) Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol. Appl. Neurobiol. 33:344-59.
5. Porreca E, et al. (1999) Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb. Haemost. 81:543-6.
6. Mourkioti F, Rosenthal N. (2008) NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J. Mol. Med. (Berl.) 86:747-59.
7. Li H, Lin X. (2008) Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine. 41:1-8.
8. Kumar A, Boriek AM. (2003) Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J. 17:386-96.
9. Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G. (2003) Activation of nuclear factorkappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology. 60:993-7.
10. Messina S, et al. (2011) Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol. 30:16-23.
11. Cai D, et al. (2004) IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 119:285-98.
12. Kumamoto T, et al. (2000) Proteasome expression in the skeletal muscles of patients with muscular dystrophy. Acta Neuropathol. 100:595-602.
13. Hasselgren P-O. (2007) Ubiquitination, phosphorylation, and acetylation: triple threat in muscle wasting. J. Cell. Physiol. 213:679-89.
14. Rudnicki MA, et al. (1993) MyoD or Myf-5 is required for the formation of skeletal muscle. Cell. 75:1351-9.
15. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS. (2000) NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 289:2363-6.
16. Hnia, et al. (2008) L-arginine decreases inflammation and modulates the nuclear factor-aB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 172:1509-19.
17. Pan Y, et al. (2008) Curcumin alleviates dystrophic muscle pathology in mdx mice. Mol. Cells. 25:531-7.
18. Messina S, et al. (2011) The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-alpha activation and ameliorates muscle function and morphology in mdx mice. Neuromuscul. Disord. 21:579-89.
19. Reay DP, et al. (2011) Systemic delivery of NEMO binding domain/IKKgamma inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol. Dis. 43:598-608.
20. Lin S-C, et al. (2008) Molecular basis for the unique deubiquitinating activity of the NFkappaB inhibitor A20. J. Mol. Biol. 376:526-40.
21. Wertz IE, et al. (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 430:694-9.
22. Charan RA, Hanson R, Clemens PR. (2012) Deubiquitinating enzyme A20 negatively regulates NF-NB signaling in skeletal muscle in mdx mice. FASEB J. 26:587-95.
23. Inagaki K, et al. (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14:45-53.
24. Wang Z, et al. (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23:321-8.
25. Louboutin JP, Wang L, Wilson JM. (2005) Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med. 7:442-51.
26. Wang B, et al. (2008) Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther. 15:1489-99.
27. Hayden MS, Ghosh S. (2004) Signaling to NFkappaB. Genes Dev. 18:2195-224.
28. Tisdale MJ. (2005) The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J. Support. Oncol. 3:209-17.
29. Grounds MD. (1991) Towards understanding skeletal muscle regeneration. Pathol. Res. Pract. 187:1-22.
30. Sethi G, Sung B, Aggarwal BB. (2008) Nuclear factor-kappaB activation: from bench to bedside. Exp. Biol. Med. (Maywood) 233:21-31.
31. Bakkar N, et al. (2008) IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J. Cell Biol. 180:787-802.
32. Deconinck N, Bernard D. (2007) Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol. 36:1-7.
33. Ervasti JM. (2007) Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim. Biophys. Acta. 1772:108-17.
34. Tang Y, et al. (2010) Inhibition of the IKK/NFkappaB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther. 17:1476-83.
35. Glass DJ. (2005) Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37:1974-84.
36. Kandarian SC, Jackman RW. (2006) Intracellular signaling during skeletal muscle atrophy. Muscle Nerve. 33:155-65.
37. Spencer MJ, Tidball JG. (2001) Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul. Disord. 11:556-64.
38. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG. (2001) Helper (CD4(+) and cytotoxic (CD8(+) T cells promote the pathology of dystrophin-deficient muscle. Clin. Immunol. 98:235-43.
39. Mcdouall RM, Dunn MJ, Dubowitz V. (1990) Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J. Neurol. Sci. 99:199-217.
40. Rosenschein U, et al. (1987) Human muscle-derived, tissue specific, myocytotoxic T cell lines in dermatomyositis. Clin. Exp. Immunol. 67:309-18.
41. Jayandharan GR, et al. (2011) Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proc. Natl. Acad. Sci. U. S. A. 108:3743-8.
42. Inagaki K, et al. (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14:45-53.
43. Grimm D, et al. (2003) Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood. 102:2412-9.
44. Inagaki K, Piao C, Kotchey NM, Wu X, Nakai H. (2008) Frequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver. J. Virol. 82:9513-24.
45. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. (1999) NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19:5785-99.
46. Eghtesad S, Jhunjhunwala S, Little SR, Clemens PR. (2011) Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle. Mol. Med. 17:917-24.